{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T01:00:27Z","timestamp":1793667627325,"version":"4.5.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016545","name":"Roche Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016545","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.tjpad.2026.100534","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T23:43:24Z","timestamp":1774482204000},"page":"100534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Performance of a fully automated plasma tau phosphorylated at threonine 217 immunoassay to reflect amyloid-beta burden in an unselected cohort representative of clinical practice"],"prefix":"10.1016","volume":"13","author":[{"given":"Sayuri","family":"Hortsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annunziata Di","family":"Domenico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Borlinghaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1716-0391","authenticated-orcid":false,"given":"David","family":"Caley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Kaminioti-Dumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Bohn","family":"Jeppesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Gonz\u00e1lez-Escalante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5124-4417","authenticated-orcid":false,"given":"Kristian Steen","family":"Frederiksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Su\u00e1rez-Calvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.tjpad.2026.100534_bib0001","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","article-title":"The neuropathological diagnosis of Alzheimer\u2019s disease","volume":"14","author":"DeTure","year":"2019","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.tjpad.2026.100534_bib0002","series-title":"US prescribing information: KISUNLA (donanemab-azbt) injection, for intravenous use","author":"Eli","year":"2024"},{"key":"10.1016\/j.tjpad.2026.100534_bib0003","series-title":"US prescribing information: LEQEMBITM (lecanemab-irmb) injection, for intravenous use","year":"2025"},{"key":"10.1016\/j.tjpad.2026.100534_bib0004","doi-asserted-by":"crossref","DOI":"10.1177\/1179573520907397","article-title":"Current and future treatments in Alzheimer disease: an update","volume":"12","author":"Yiannopoulou","year":"2020","journal-title":"J Cent Nerv Syst Dis"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100534_bib0005","article-title":"Blood-based biomarkers in Alzheimer's disease: future directions for implementation","volume":"15","author":"Suridjan","year":"2023","journal-title":"Alzheimers Dement (Amst)"},{"issue":"8","key":"10.1016\/j.tjpad.2026.100534_bib0006","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100534_bib0007","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14508","article-title":"The Alzheimer's Association Global Biomarker Standardization Consortium (GBSC) plasma phospho-tau round robin study","volume":"21","author":"Ashton","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.1016\/j.tjpad.2026.100534_bib0008","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14609","article-title":"A head-to-head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic","volume":"21","author":"Anastasi","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"12","key":"10.1016\/j.tjpad.2026.100534_bib0011","doi-asserted-by":"crossref","first-page":"9037","DOI":"10.1002\/alz.14336","article-title":"Centiloid recommendations for clinical context-of-use from the AMYPAD consortium","volume":"20","author":"Collij","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100534_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2025.103765","article-title":"A practical overview of the use of amyloid-PET centiloid values in clinical trials and research","volume":"46","author":"Iaccarino","year":"2025","journal-title":"Neuroimage Clin"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100534_bib0013","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13195-019-0478-z","article-title":"Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers","volume":"11","author":"Salvad\u00f3","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.tjpad.2026.100534_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmp.2024.103345","article-title":"Amyloid brain-dedicated PET images can diagnose Alzheimer's pathology with Centiloid Scale","volume":"121","author":"Gandia-Ferrero","year":"2024","journal-title":"Phys Med"},{"issue":"6","key":"10.1016\/j.tjpad.2026.100534_bib0015","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"issue":"10518","key":"10.1016\/j.tjpad.2026.100534_bib0016","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/S0140-6736(25)01853-7","article-title":"Global, regional, and national burden of chronic kidney disease in adults, 1990-2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","author":"Mark","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100534_bib0017","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.52387","article-title":"Association of kidney function with development of alzheimer disease and other dementias and dementia-related blood biomarkers","volume":"6","author":"Stocker","year":"2023","journal-title":"JAMA Network Open"},{"issue":"12","key":"10.1016\/j.tjpad.2026.100534_bib0018","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease","volume":"18","author":"Hansson","year":"2022","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100534_bib0019","unstructured":"Perneczky R, Stoeckl L, Carboni M, et al. Head-to-head comparison of the fully automated Elecsys pTau217 plasma assay and the Lumipulse pTau217 plasma assay. In: Clinical Trials on Alzheimer's Disease conference (CTAD); 2024. 29 October\u20131 November 2024. Poster LP069."},{"issue":"1","key":"10.1016\/j.tjpad.2026.100534_bib0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/jnc.15757","article-title":"Impact of pre-analytical sample handling factors on plasma biomarkers of Alzheimer's disease","volume":"165","author":"Kurz","year":"2023","journal-title":"J Neurochem"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100534_bib0021","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1002\/alz.12751","article-title":"An accurate fully automated panel of plasma biomarkers for Alzheimer's disease","volume":"19","author":"Palmqvist","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2026.100534_bib0022","series-title":"US prescribing information: NEURACEQ (florbetaben F 18 injection), for intravenous use","year":"2014"},{"key":"10.1016\/j.tjpad.2026.100534_bib0023","series-title":"US prescribing information: VIZAMYL\u2122 (flutemetamol F 18 injection) for intravenous use","year":"2017"},{"key":"10.1016\/j.tjpad.2026.100534_bib0024","series-title":"US prescribing information: Amyvid (Florbetapir F 18 injection) for intravenous use","author":"Eli","year":"2012"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100534_bib0025","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"issue":"4s","key":"10.1016\/j.tjpad.2026.100534_bib0026","first-page":"S117","article-title":"Kidney Disease: improving global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.tjpad.2026.100534_bib0027","unstructured":"National Kidney Foundation. CKD-EPI creatinine equation (2021), https:\/\/www.kidney.org\/ckd-epi-creatinine-equation-2021-0; [accessed 14 January 2026]."},{"issue":"1","key":"10.1016\/j.tjpad.2026.100534_bib0028","article-title":"Blood-based biomarkers for Alzheimer's pathology and the diagnostic process for a disease-modifying treatment: projecting the impact on the cost and wait times","volume":"12","author":"Mattke","year":"2020","journal-title":"Alzheimers Dement (Amst)"},{"issue":"7","key":"10.1016\/j.tjpad.2026.100534_bib0029","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","article-title":"Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's disease","volume":"20","author":"Schindler","year":"2024","journal-title":"Nat Rev Neurol"},{"issue":"7","key":"10.1016\/j.tjpad.2026.100534_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70535","article-title":"Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings","volume":"21","author":"Palmqvist","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.tjpad.2026.100534_bib0031","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210287","article-title":"Quantitative assessment of the effect of chronic kidney disease on plasma P-Tau217 concentrations","volume":"104","author":"Bornhorst","year":"2025","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.tjpad.2026.100534_bib0032","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.3390\/biomedicines12081836","article-title":"P-tau217 as a reliable blood-based marker of Alzheimer's disease","volume":"12","author":"Lai","year":"2024","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100534_bib0033","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/s41598-024-51334-x","article-title":"Clinical evaluation of a novel plasma pTau217 electrochemiluminescence immunoassay in Alzheimer's disease","volume":"14","author":"Kivis\u00e4kk","year":"2024","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100534_bib0034","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/brain\/awac333","article-title":"Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease","volume":"146","author":"Janelidze","year":"2023","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100534_bib0035","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/alz.12841","article-title":"Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays","volume":"19","author":"Ashton","year":"2023","journal-title":"Alzheimers Dement"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100534_bib0036","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/s13195-021-00939-9","article-title":"Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231","volume":"13","author":"Bayoumy","year":"2021","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"10.1016\/j.tjpad.2026.100534_bib0037","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","article-title":"Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests","volume":"30","author":"Barth\u00e9lemy","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100534_bib0038","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13195-022-01003-w","article-title":"The cerebrospinal fluid biomarker ratio A\u03b242\/40 identifies amyloid positron emission tomography positivity better than A\u03b242 alone in a heterogeneous memory clinic cohort","volume":"14","author":"Amft","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"9","key":"10.1016\/j.tjpad.2026.100534_bib0039","first-page":"1797","article-title":"Plasma p-tau231 and p-tau217 as state markers of amyloid-\u03b2 pathology in preclinical Alzheimer's disease","volume":"28","author":"Mil\u00e0-Alom\u00e0","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.tjpad.2026.100534_bib0040","doi-asserted-by":"crossref","DOI":"10.1002\/alz.71009","article-title":"Elecsys pTau217 plasma immunoassay detection of amyloid pathology in clinical cohorts","volume":"22","author":"Hibar","year":"2026","journal-title":"Alzheimer's & Dementia"},{"issue":"5","key":"10.1016\/j.tjpad.2026.100534_bib0041","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-019-0250-2","article-title":"Diagnosis of Alzheimer's disease utilizing amyloid and tau as fluid biomarkers","volume":"51","author":"Lee","year":"2019","journal-title":"Exp Mol Med"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726000580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580726000580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:57:50Z","timestamp":1792724270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580726000580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2274580726000580"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100534","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Performance of a fully automated plasma tau phosphorylated at threonine 217 immunoassay to reflect amyloid-beta burden in an unselected cohort representative of clinical practice","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2026.100534","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100534"}}